[TF-KY] Subsidiary Taiwan TF Biotech Announces Capital Reduction to Offset Losses and Creditor Notification
Key facts
- [TF-KY] Subsidiary Taiwan TF Biotech Announces Capital Reduction to Offset Losses and Creditor Notification
- Taiwan TF Biotech has resolved to carry out a 99.4% capital reduction to improve its financial structure. The reduction amount is NT$2.496 billion, with the decision made by the board due to a single-shareholder structure.
- Source: TWSE
- Date: Mon Jun 22 2026 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
Taiwan TF Biotech has resolved to carry out a 99.4% capital reduction to improve its financial structure. The reduction amount is NT$2.496 billion, with the decision made by the board due to a single-shareholder structure.
- Citation
- [TF-KY] Subsidiary Taiwan TF Biotech Announces Capital Reduction to Offset Losses and Creditor Notification (Mon Jun 22 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Mon Jun 22 2026 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Taiwan TF Biotech has resolved to carry out a 99.4% capital reduction to improve its financial structure. The reduction amount is NT$2.496 billion, with the decision made by the board due to a single-shareholder structure.
AI Analysis
Frequently Asked Questions
- Q: What is the capital reduction ratio of Taiwan TF Biotech?
- A: The reduction ratio is 99.40255872%, nearly a full capital cut.
- Q: Why is the company reducing capital?
- A: To improve financial structure in line with group operational planning.
- Q: What will be the paid-in capital after reduction?
- A: It will be reduced to NT$15 million.
- Q: What should creditors do?
- A: Creditors must submit written objections within 31 days of the announcement.
- Q: Who made this resolution?
- A: The chairman exercised shareholder authority due to single legal shareholder structure.